Go to content
UR Home

Targeted tumor therapy with the TGF-beta2 antisense compound AP 12009

DOI to cite this document:
Schlingensiepen, Karl-Hermann ; Schlingensiepen, Reimar ; Steinbrecher, Andreas ; Hau, Peter ; Bogdahn, Ulrich ; Fischer-Blass, Birgit ; Jachimczak, Piotr
(903kB) - Repository staff only
Date of publication of this fulltext: 05 Aug 2009 13:24


TGF-beta overexpression is a hallmark of various malignant tumors. This is due to the pivotal role of TGF-beta as it regulates key mechanisms of tumor development, namely immunosuppression, metastasis, angiogenesis, and proliferation. We have developed a new immunotherapeutic approach for the treatment of malignant tumors based on the specific inhibition of TGF-beta2 by the antisense ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: daten@ur.de
0941 943 -5707

Contact persons